Novavax COVID-19 booster shot granted EUA for adults
marketwatch.com
news
2022-10-19 15:20:08

Shares of Novavax Inc. NVAX, +2.95% rallied 1.9% in morning trading Wednesday, after the biotechnology company said its protein-based COVID-19 vaccine booster was granted emergency use authorization (EUA) for adults. The booster shot is OK'd for people at least 18 years old who have completed primary vaccinations. The company said in trials, any local and systemic reactions from the booster had a median duration of about two days. Of those receiving the booster, 81.1% had pain/tenderness at the sight of the shot, 63.
